Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting

June 1, 2021 12:30 UTC

 

Webcast scheduled for Tuesday, June 8, 2021, at 12:00 pm ET

 

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the company will host a conference call and webcast to review updated 90-day efficacy, safety and pharmacokinetic data from its ongoing multicenter Phase 1 clinical trial of JSP191, the company’s anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning regimen in older patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) undergoing allogeneic hematopoietic (blood) cell transplantation.

The webcast, which will take place on Tuesday, June 8, 2021 at 12:00 pm ET, will include presentations from Jasper management, along with guest speakers:

  • Lori Muffly, M.D., M.S., Assistant Professor of Medicine (Blood and Bone Marrow Transplantation) at Stanford Medicine and lead investigator of the study. Dr. Muffly will present the JSP191 data in a poster session at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held online June 4-8, 2021.
  • Gail Roboz, M.D., Professor of Medicine (Hematology and Medical Oncology) and Director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine.

Conference Call and Webcast Details:
A live webcast of the event, including presentation slides, will be available on Tuesday, June 8, 2021 at 12:00 pm ET by clicking here. To access the investor event by phone and participate in the question and answer session, dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and reference conference ID: 13720248. A replay of the webcast will be available for 90 days following the live event.

About MDS and AML
Myelodysplastic syndromes (MDS) are a group of disorders in which immature blood-forming cells in the bone marrow become abnormal and do not make new blood cells or make defective blood cells, leading to low numbers of normal blood cells, especially red blood cells.i In about one in three patients, MDS can progress to acute myeloid leukemia (AML), a rapidly progressing cancer of the bone marrow cells.i Both are diseases of the elderly with high mortality. Each year, about 29,000 patients are diagnosed with MDS and approximately 42,000 patients are diagnosed with AML in the G7 countries for which approximately 2,500 patients with MDS and approximately 8,000 people with AML receive hematopoietic stem cell transplants. While hematopoietic cell transplantation is potentially curative in these patients, its use is limited in older and frail patients because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy.

About JSP191
JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) and expects to begin enrollment in three additional studies in 2021 for severe autoimmune disease, sickle cell disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases.


i American Cancer Society. About Myelodysplastic Syndromes. https://www.cancer.org/cancer/myelodysplastic-syndrome/about/what-is-mds.html. Accessed May 3, 2021.

Contacts

Lily Eng
Real Chemistry
206-661-8627
leng@realchemistry.com

Jeet Mahal
Jasper Therapeutics
650-549-1403
jmahal@jaspertherapeutics.com

 
 

Source: Jasper Therapeutics, Inc.

Back to news